Dapivirine Ring and Oral PrEP in Pregnancy: MTN-042/DELIVER Shows Infant Safety Through 12 Months
Highlight
– MTN-042/DELIVER randomized pregnant, HIV-negative women to dapivirine vaginal ring (DVR) or daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and followed 545 infants to 12 months.
– Composite infant safety events (serious adverse events or grade ≥3 adverse events) occurred but were not attributed to study product; no maternal or infant HIV infections were observed.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.